Search

Displaying results 2841 - 2850 of 6197 in total
  1. Drug

    Matrix-M

    go.drugbank.com/drugs/DB16369
    Investigational

    Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax.

  2. Drug

    Magnesium gluconate

    go.drugbank.com/drugs/DB13749
    ApprovedWithdrawn

    Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an ingredient in some medicines (such as antacids

    Mixtures: K-med
  3. Drug

    Levonordefrin

    go.drugbank.com/drugs/DB06707
    ApprovedInvestigational

    Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.

  4. Drug

    BK-MDA

    go.drugbank.com/drugs/DB12809
    Investigational

    BK-MDA has been used in trials studying the treatment of Bladder Exstrophy and Urinary Incontinence.

    Synonyms: BK-MDA
  5. Indication

    Hereditary Retinoblastoma

    go.drugbank.com/conditions/DBCOND0083136
    Drugs: Carboplatin · Cyclophosphamide · Etoposide · Vincristine
    Synonyms: Malignant tumour of eye: [Ca eye] or [malignant melanoma] or [retinoblastoma]
  6. Drug

    Benfluorex

    go.drugbank.com/drugs/DB09022
    ApprovedWithdrawn

    Benfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine. It was patented and manufactured by a French pharmaceutical company Servier.

  7. Drug

    Silodosin

    go.drugbank.com/drugs/DB06207
    ApprovedInvestigational

    [A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … [A231159] Silodosin works by binding to α<sub>1A</sub>-adrenoceptors with high affinity and relaxing the lower urinary tract, thereby improving urinary symptoms and alleviating bladder outlet obstruction

  8. Drug

    Flutamide

    go.drugbank.com/drugs/DB00499
    ApprovedInvestigational

    An antiandrogen with about the same potency as cyproterone in rodent and canine species.

  9. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335] and in the US in March 2024.[L50291,L50296] … [A249920] It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since become one of the most popular cosmetic procedures worldwide.

  10. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379] … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12